# Nuclide record nct05682443 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct05682443/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct05682443", "NCT05682443" ;
  schema:name "ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC"@en ;
  schema:alternateName "PRESERVE-006"@en ;
  schema:description "A phase 1/2 trial of Gotistobart, Lutetium-177 vipivotide tetraxetan in prostate cancer, run by OncoC4, Inc., active and no longer recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct05682443/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05682443> ;
  nuclide:status "active" ;
  nuclide:tag "ctgov-ingest" ;
  nuclide:phase "1/2" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/prostate-mcrpc/> ;
  nuclide:drugs <https://nuclide.cc/drugs/pluvicto/> .